Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Bolsa de Madrid  >  Grifols    GRF   ES0171996087

GRIFOLS (GRF)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Bolsa De Madrid
07/13/2018 07/16/2018 07/17/2018 07/18/2018 07/19/2018 Date
25.58(c) 25.6(c) 25.67(c) 25.42(c) 25.04 Last
465 863 457 678 1 014 270 855 282 1 434 485 Volume
-0.47% +0.08% +0.27% -0.97% -1.49% Change
More quotes
Financials (EUR)
Sales 2018 4 454 M
EBIT 2018 1 114 M
Net income 2018 652 M
Debt 2018 4 971 M
Yield 2018 1,51%
Sales 2019 4 699 M
EBIT 2019 1 224 M
Net income 2019 744 M
Debt 2019 4 576 M
Yield 2019 1,65%
P/E ratio 2018 25,91
P/E ratio 2019 23,12
EV / Sales2018 4,66x
EV / Sales2019 4,34x
Capitalization 15 801 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments:... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of Grifols
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS
07/10GRIFOLS : newest angel of elBullifoundation
AQ
07/03GRIFOLS : discloses transfers of value made to European healthcare professionals..
AQ
06/25GRIFOLS : FDA Clears Anti-Neutrophil Cytoplasmic Antibody Test for Vasculitis, a..
AQ
06/01GRIFOLS : Ex-dividend day for final dividend
FA
05/31GRIFOLS : Researchers Submit Patent Application, "In Vitro Diagnostic Method for..
AQ
05/31GRIFOLS : Reports from Grifols Describe Recent Advances in Alzheimer Disease (In..
AQ
05/28GRIFOLS : culminates a year of growth and approves the distribution of a record ..
AQ
05/10GRIFOLS : Patent Issued for Purification of Cell Culture Derived Alpha1 Protease..
AQ
05/09GRIFOLS : increases its net profit by 7% to Euros 143 million and delivers signi..
AQ
05/04GRIFOLS : announces Q1 2018 financial results
AQ
More news
Sector news : Biopharmaceuticals
07/19AMGEN : and Cedars-Sinai in Collaboration for 'Health-Care Quality'
DJ
07/19MERCK AND : to Limit Drug-Price Increases, Cut Some Prices
DJ
07/19MERCK AND : Announces Plan to Lower Prices of Some Drugs
DJ
07/19JOHNSON & JOHNSON : Women who sued J&J declare victory after $4.69 billion talc ..
RE
07/19Barclays Poaches Senior Health-Care Banker From Deutsche Bank
DJ
More sector news : Biopharmaceuticals
Latest Tweets
07/13GRIFOLS S A/S $GRFS Cut to Strong Sell at BidaskClub  
07/10Brokerages Set GRIFOLS S A/S $GRFS Target Price at $22.00  
07/06Aradigm Announces the Appointment of Dr. Theresa Matkovits to the Board of Di.. 
07/06Aradigm Announces the Appointment of Dr. Theresa Matkovits to the Board of Di.. 
07/06Takeda and TiGenix Announce Results of Second Acceptance Period for the Volun.. 
More tweets
Qtime:73
News from SeekingAlpha
06/08Grifols (GIKLY) Investor Presentation - Slideshow 
02/02ARADIGM : Points Of Discussion 
01/313 THINGS IN BIOTECH YOU SHOULD LEARN : January 30, 2018 
01/143 THINGS IN BIOTECH YOU SHOULD LEARN : January 13, 2018 
2017Why The Catalan Election Won't Affect Your Spanish Stocks In The Long Run 
Chart GRIFOLS
Duration : Period :
Grifols Technical Analysis Chart | GRF | ES0171996087 | 4-Traders
Technical analysis trends GRIFOLS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 24
Average target price 26,7 €
Spread / Average Target 5,2%
EPS Revisions
Managers
NameTitle
Raimon Grifols Roura Joint Chief Executive Officer & Director
Victor Grifols Deu Joint Chief Executive Officer & Executive Director
Víctor Grifols Roura Non-Executive Chairman
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Vicente Blanquer Torre Vice President-Quality, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS4.07%18 309
BIOGEN12.54%74 904
CSL LIMITED41.27%66 152
ALEXION PHARMACEUTICALS13.43%30 349
BIOMARIN PHARMACEUTICAL15.16%18 364
WUXI BIOLOGICS CAYMAN INC--.--%12 853